Vonoprazan 20 mg
DrugVonoprazan PO, 20mg, once a day, 14 days.
Other names: vocinti
NCT Number: NCT06720610
The goal of this clinical trial is to compare drug vonoprazan vs esomeprazole effectiveness to relieve early symptoms in Erosive Esophagitis Patients. It will also learn about the safety of both modalities. The main questions it aims to answer are:
How does the effectiveness of Vonoprazan compare with Esomeprazole in improving early symptoms of erosive esophagitis patients in the Indonesian population?
Researchers will compare drug vonoprazan to a esomeprazole with a look-alike packaging to see their effect to reduce early symptoms of erosive esophagitis.
Participants will:
* Take drug vonoprazan 20mg or esomeprazole 40mg one time every day for 2 weeks * Visit the clinic once every weeks for followup (Gastro Esophageal Reflux Disease-Quetionnaire measurement) * Keep a diary of their adverse effect occurence and every variable data based on Gastro Esophageal Reflux Disease-Questionnaire.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 4
Hermina Jatinegara Hospital, East Jakarta, DKI Jakarta, Indonesia
Based on the calculation using the formula for comparing two population proportions, the minimum estimated sample size is 97 samples for each group. Considering a potential 10% drop-out rate, the estimated sample size increases to 108 samples per group. Therefore, the total minimum sample required for this study is 216 samples for both groups.
All the patients will screened using the Gastro Esophageal Reflux Disease-Quetionnaire (6 questions, 4 answer options, covering the last 7 days) and collected through RedCap. After that all eligible patients will undergo endoscopic examination that performed by gastroenterology specialists or trained internists.
Included patients who consume any Proton Pump Inhibiotr or Potassium-competitive acid blockers within 2 weeks prior to this study will undergo wash-out period for 2 weeks. Patients are monitored weekly during the wash-out period. Medication reminders are sent via instant messaging at least twice per week. Adverse Event will be monitored by research assistants in coordination with the patient's primary physician.
All the data will analyzed blindly with Chi-square or Fisher's exact test for categorical data and logistic regression for confounding factors. At the end of the study, the pharmacy team will reveal the group allocation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Vonoprazan PO, 20mg, once a day, 14 days.
Other names: vocinti
Esomeprazole PO, 40mg, once a day, 14 days
Other names: Esomeprazole generic
Time frame: 14 days (two weeks)
Participants achieved a,
Time frame: 14 days (two weeks)
Yes: nasopharyngitis, diarrhea, acute upper respiratory infection, lower back pain, constipation No: none of any
Time frame: 14 days (two weeks)
Compliant (14 drugs finished in 14 days) Lack of compliance (14 drugs finished in >14 days) Non-compliant (not taking drugs)
Contact information is provided by the study sponsor or research team.
Ari F Syam, MD
CONTACT
Ryan Herardi, MD
CONTACT
Indonesia University
Other
Comparison of the Effectiveness of Vonoprazan and Esomeprazole in Improving Initial Symptoms in Patients with Erosive Esophagitis: a Double-Blind Randomized Trial
Acronym: INVEST
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05267613
Deglutition Disorders, Digestive System Diseases
Mobile, Alabama, United States
View Trial DetailsNCT05055128
Erosive Esophagitis
Tampa, Florida, United States
View Trial DetailsNCT05587309
Erosive Esophagitis
Homewood, Alabama, United States
View Trial DetailsNCT05890001
Deglutition Disorders, Digestive System Diseases
Huntsville, Alabama, United States
View Trial Details